Industrialization, quality and sovereignty: building a stronger and more competitive European HealthTech ecosystem

At the 12th edition of France Biotech’s “100% HealthTech” live show, Efor’s COO Julie Marion joined journalist Fabrice Lundy to share her insights on what it really takes to bring health innovations to industrial scale in Europe — and why this moment is critical for the continent’s competitiveness. 

This event has become a must-follow for the European health community, spotlighting industrial breakthroughs and the strategic forces reshaping today’s HealthTech landscape. 

Europe’s industrialization challenge: talent, capacity and regulatory consistency

Europe’s scientific ecosystem is world-class. 
But turning scientific promise into solutions for patients requires navigating three major realities: 

• A strong but inconsistently applied regulatory framework, with EMA, MDR and IVDR interpreted differently across countries. 

• Industrial capacity still catching up, especially in fast-growing areas like biotherapies, vaccines and digital medical devices. 

• A booming demand for technical expertise — from production to quality to CQV — in a job market under high tension. 

Rather than roadblocks, Julie sees these as growth levers that can reinforce Europe’s industrial sovereignty: expanding GMP capacity, aligning practices and making the continent more attractive to top talent. 

Regulation as a growth engine — not a constraint 

One message clearly stood out: compliance is not a burden. It’s a competitive advantage. 
And at Efor, it’s a conviction we see confirmed every day. 

Teams that integrate regulatory expectations early on — and approach quality standards with pragmatism rather than fear — can: 

• drastically reduce back-and-forth with regulators, 

• accelerate key evaluation stages, 

• and build stronger credibility with partners and investors. 

Julie also highlighted a major asset: companies that meet European expectations are better positioned globally, as EU standards are highly regarded by the FDA, PMDA and other major agencies. 

Quality, compliance and speed: the new strategic equation 

A point often overlooked: quality has become one of the most powerful differentiators in HealthTech. 

Embedding quality and risk management from day one enables companies to: 

• accelerate time-to-market, 

• secure trials and scale-up, 

• strengthen trust among clinicians and patients, 

• and convince industrial partners who now prioritize low-risk, well-controlled projects. 

In a market where every month counts — not only for growth but for patient access — mastering industrialization is now a core strategic capability. 

With 3,200+ employees across 18 countries, Efor supports health innovators every day on their industrialization and quality challenges. 
Our mission is clear: helping them meet compliance expectations through deep technical expertise in industrialization and manufacturing. 

Our global and local footprint allows us to leverage diverse experience to streamline, secure and scale projects, no matter their maturity level. 

🎥 Watch the full interview